Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Chaopin Yang"'
Autor:
Chaopin Yang, Jinqi You, Qiuzhong Pan, Yan Tang, Liming Cai, Yue Huang, Jiamei Gu, Yizhi Wang, Xinyi Yang, Yufei Du, Dijun Ouyang, Hao Chen, Haoran Zhong, Yongqiang Li, Jieying Yang, Yulong Han, Fengze Sun, Yuanyuan Chen, Qijing Wang, Desheng Weng, Zhongqiu Liu, Tong Xiang, Jianchuan Xia
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-19 (2023)
Abstract Background CD133 is considered a marker for cancer stem cells (CSCs) in several types of tumours, including hepatocellular carcinoma (HCC). Chimeric antigen receptor-specific T (CAR-T) cells targeting CD133-positive CSCs have emerged as a to
Externí odkaz:
https://doaj.org/article/10923eba8c51443a882b030449ddfcf7
Autor:
Jieying Yang, Zhixing Guo, Mengjia Song, Qiuzhong Pan, Jingjing Zhao, Yue Huang, Yulong Han, Dijun Ouyang, Chaopin Yang, Hao Chen, Muping Di, Yan Tang, Qian Zhu, Qijing Wang, Yongqiang Li, Jia He, Desheng Weng, Tong Xiang, JianChuan Xia
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionThe limited response to immune checkpoint blockades (ICBs) in patients with hepatocellular carcinoma (HCC) highlights the urgent need for broadening the scope of current immunotherapy approaches. Lenvatinib has been shown a potential syne
Externí odkaz:
https://doaj.org/article/207e3cc2570549e2ad4638ce40e5d928
Autor:
Yulong Han, Qiuzhong Pan, Zhixing Guo, Yufei Du, Yaojun Zhang, Yingying Liu, Jingjing Zhao, Jinfeng Xu, Jieying Yang, Dijun Ouyang, Yan Tang, Qijing Wang, Yongqiang Li, Jia He, Mengjuan Yang, Hao Chen, Chaopin Yang, Xinyi Yang, Jinqi You, Yuanyuan Chen, Minghao Ren, Yao Zhu, Jianchuan Xia, Tong Xiang
Publikováno v:
Clinical and Translational Medicine, Vol 13, Iss 5, Pp n/a-n/a (2023)
Abstract Background In the past decade, the field of tumour immunotherapy has made a great progress. However, the efficacy of immune checkpoint blocking (ICB) in the treatment of hepatocellular carcinoma (HCC) remains limited. Cytotoxic lymphocyte tr
Externí odkaz:
https://doaj.org/article/0a377928649140ec94b0fc63caa47d4b
Autor:
Yue Huang, Yingqin Zhu, Jieying Yang, Qiuzhong Pan, Jingjing Zhao, Mengjia Song, Chaopin Yang, Yulong Han, Yan Tang, Qijing Wang, Jia He, Yongqiang Li, Junyi He, Hao Chen, Desheng Weng, Tong Xiang, Jian Chuan Xia
Publikováno v:
Cell Death and Disease, Vol 13, Iss 3, Pp 1-13 (2022)
Abstract Hepatocellular carcinoma is one of the most common malignancies and has a poor prognosis. The ubiquitin-proteasome pathway is required for the degradation of most short-lived proteins. CMTM6 has been implicated in the progression of various
Externí odkaz:
https://doaj.org/article/30ca25d372814bf58afd33c9d4fc8ce8
Autor:
Fengze Sun, Yuanyuan Liu, Tingting Gong, Qiuzhong Pan, Tong Xiang, Jingjing Zhao, Yan Tang, Hao Chen, Yulong Han, Mengjia Song, Yue Huang, Han Li, Yuanyuan Chen, Chaopin Yang, Jieying Yang, Qijing Wang, Yongqiang Li, Jia He, Desheng Weng, Ruiqing Peng, Jianchuan Xia
Publikováno v:
Cell Death and Disease, Vol 12, Iss 12, Pp 1-9 (2021)
Abstract Most patients with hepatocellular carcinoma (HCC) are in the middle or advanced stage at the time of diagnosis, and the therapeutic effect is limited. Therefore, this study aimed to verify whether deoxythymidylate kinase (DTYMK) increased in
Externí odkaz:
https://doaj.org/article/33d3a7e398e24d5bbbe7ee462a878d6f
Autor:
Xinyi Yang, Desheng Weng, Qiuzhong Pan, Tong Xiang, Chaopin Yang, Zhengrong Wu, Minxing Li, Songzuo Xie, Yan Tang, Jianchuan Xia, Jingjing Zhao
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Breast cancer is one of the most common cancers in women. Triple-negative breast cancer (TNBC) has a significantly worse prognosis due to the lack of endocrine receptors including estrogen receptor (ER), progesterone receptor (PR) and human epidermal
Externí odkaz:
https://doaj.org/article/843cb2cabc0e4e54b69940a8196f7b3a
Autor:
Jingjing Zhao, Yue Li, Yan Tang, Jian-Chuan Xia, Yue Huang, Mian He, Weijing Zhang, Libing Song, Han Li, Fan Luo, Xingyu Jiang, Tong Xiang, Qiuzhong Pan, Liming Cai, Desheng Weng, Yuhu Dai, Fengze Sun, Chaopin Yang, Jieying Yang, Yulong Han, Yanna Zhang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background Platinum resistance is a major challenge in the clinical treatment of advanced ovarian cancer (OC). Accumulating evidence shows that the tumor-promotive M2 macrophage is linked to the limiting chemotherapy efficacy of multiple malignancies
Externí odkaz:
https://doaj.org/article/b3ecd8d9c48e43f58bbd14e9d4f6ec45
Autor:
Meng‐Jia Song, Qiu‐Zhong Pan, Ya Ding, Jianxiong Zeng, Pei Dong, Jing‐Jing Zhao, Yan Tang, Jingjing Li, Zhiling Zhang, Junyi He, Jieying Yang, Yue Huang, Ruiqing Peng, Qi‐Jing Wang, Jia‐Mei Gu, Jia He, Yong‐Qiang Li, Shi‐Ping Chen, Rongxing Huang, Zi‐Qi Zhou, Chaopin Yang, Yulong Han, Hao Chen, Heping Liu, Shangzhou Xia, Yang Wan, De‐Sheng Weng, Liming Xia, Fang‐Jian Zhou, Jian‐Chuan Xia
Publikováno v:
Clinical & Translational Immunology, Vol 10, Iss 3, Pp n/a-n/a (2021)
Abstract Objectives Although axitinib has achieved a preferable response rate for advanced renal cell carcinoma (RCC), patient survival remains unsatisfactory. In this study, we evaluated the efficacy and safety of a combination treatment of axitinib
Externí odkaz:
https://doaj.org/article/207802f67c564291ab3647874de5462f
Publikováno v:
Journal of Immunology Research, Vol 2020 (2020)
NK cells are lymphocytes with antitumor properties and can directly lyse tumor cells in a non-MHC-restricted manner. However, the tumor microenvironment affects the immune function of NK cells, which leads to immune evasion. This may be related to th
Externí odkaz:
https://doaj.org/article/73e479867a7e479da46cfd476b1ecde9
Autor:
Heping Liu, Yuxiang Ma, Chaopin Yang, Shangzhou Xia, Qiuzhong Pan, Hongyun Zhao, Wenfeng Fang, Xi Chen, Yang Zhang, Benyan Zou, Qiuyuan Li, Yang Wan, Hao Chen, Yan Tang, Jingjing Zhao, Desheng Weng, Liming Xia, Li Zhang, Jianchuan Xia
Publikováno v:
Clinical & Translational Immunology, Vol 9, Iss 10, Pp n/a-n/a (2020)
Abstract Objectives This phase I study aimed to evaluate the antitumor effect and safety of programmed death‐ligand‐1 (PD‐L1)–targeting autologous chimeric antigen receptor T (CAR‐T) cells for patients with non‐small cell lung cancer (NSC
Externí odkaz:
https://doaj.org/article/c59e00c92e2b4c99a025ccb663771fe4